The human c-myc proto-oncogene is a cellular gene homologous with the 3' sequence of the transforming gene of the avian myelocytomatosis virus MC29 (Papas et al., 1984) . It has been shown that in Burkitt lymphoma-derived cell lines the c-myc proto-oncogene is often involved in reciprocal translocations involving the immunoglobulin genes although the chromosomal break points may differ (Gellmann et al., 1983; Erikson et al., 1983; Hayday et al., 1984) ; in some circumstances this appears to be associated with mutation of c-myc . This type of rearrangement has also been described in murine plasmocytoma cell lines (Bernard et al., 1983) . Rearrangement of c-myc has also been described in cell lines or fresh tissue from other lymphoid tumours, but these are less well characterised in terms of the precise genomic configuration (Rothberg et al., 1984; Dalla-Favera et al., 1983) . Rearrangements of the c-myc proto-oncogene have been correlated with elevated expression but this does not appear to be invariably the case (Klein, 1981; . In some Burkitt cell lines levels of c-myc mRNA comparable to those seen in normal cells are found, but the untranslocated allele is silent (Taub et al., 1984) . This raises the possibility that the translocation may result in expression at an inappropriate stage of cellular development. On the basis of this work, it has been suggested that J.C.-B abnormal expression of c-myc may be critically involved in development of lymphomas.
In contrast to the extensive study of Burkitt lymphoma derived cell lines there is little known about the expression of this gene in other types of lymphoid tumour or in normal lymphoid tissues. Elevated levels of c-myc mRNA have been found in some tumours (Rothberg et al., 1984; Roy-Burnam et al., 1983; Slamon et al., 1984) , but the interpretation of these results is complicated by the extensive cellular heterogeneity which may be present in malignant lymphomas.
We therefore decided to investigate c-myc expression in lymphoid tumours using monoclonal antibodies to the p62c-mYc gene product. (Wright & Isaacson, 1983; Lukes & Butler, 1966) .
Monoclonal antibodies
Two monoclonal antibodies were used. These were raised against synthetic peptides as previously described. The antibodies designated myc-I 6E10 and myc-I 9E10 have been shown to react with different regions of the p62c-mYc molecule and to be monospecific on immunoblotting with various cell lines . 
Results
Antibody specificity An identical pattern of staining was obtained using both monoclonal antibodies. (Figure la,b) . As these were raised to different parts of the p62c-mYc molecule it renders fortuitous cross reactions, commonly seen with monoclonal antibodies, unlikely.
Distribution of staining Normal lymphoid tissue All lymphoid cells seen in normal lymph node, spleen, tonsil and thymus were unstained with the exception of plasma cells (see Table I ). (Figure 2 ). These cells showed marked and consistent cytoplasmic staining. In thymus strong granular cytoplasmic staining was present in the epithelial cells including Hassall's corpuscles. In tonsil granular cytoplasmic staining was present in crypt epithelium. In both spleen and lymph node rather faint cytoplasmic staining was seen in histiocytes. This was most marked in the tingeable body histiocytes associated with germinal centres.
Intense nuclear and cytoplasmic staining was present in the majority of haemopoietic precursor cells seen in normal bone marrow (Figure la, b) . Weak cytoplasmic staining was sometimes seen in mature granulocytes.
Lymphoid tumours A summary of the staining patterns found in lymphoid tumours is given in Table II . A number of additional points should be noted. Two lymphoblastic tumours were included. In addition, large cell elements, presumably immunoblasts, were found to be stained in two cases of pleomorphic peripheral T cell tumours (Figure 4) , although most of the small or intermediate sized cells were unstained ( Figure 5 ). Two plasma cell tumours showed diffuse cytoplasmic and, occasionally nuclear staining of the type seen in normal plasma cells.
In the cases of Hodgkin's disease some ReedSternberg cells showed cytoplasmic and occasionally nuclear staining, although this was variable Normal non-lymphoid tissues Non-lymphoid cells were often present in biopsies of lymphoid tissue. As shown in Table III , a wide variety of cell types showed immunoreactivity. Some cells, such as connective tissue cells, showed diffuse cytoplasmic staining, similar to that seen in plasma cells. In other cells, notably hepatocytes and jejunal epithelium, (Figure 6 ) p62c-myc was localised to coarse, intensely staining cytoplasmic granules. The perinuclear distribution of these granules in enterocytes suggested an association with the Golgi apparatus. (Stein et al., 1984) . It was not possible to determine whether normal T-immunoblasts contained p62c-mYc since these cells are rarely seen in normal lymphoid tissue and suitable material from cases of reactive T immunoblastic hyperplasia such as infective mononucleosis was not available. Therefore it is impossible to comment on whether the tumour cells are aberrantly expressing the c-myc gene product. In cultured lymphoid cells a transient increase in levels of c-myc mRNA is found after mitogen or growth factor stimulation at the GO/G1 transition (Kelly et al., 1984) . As transcription in some systems does not appear to vary during the cell cycle, regulation of c-myc mRNA may be partly related to variable rates of degradation (Blanchard et al., 1985) . In a wide range of other cells c-myc is induced in early G1 phase and persists during S and G2 phases of the cell cycle (Rabbitts et al., 1985 and Go arrested cells such as hepatocytes. Immunoreactive c-myc product has been described in normal testicular cells (Sikora et al., 1985) . An imperfect correlation with cell division and c-myc mRNA expression has also been found using in situ hybridisation of human embryos (Pheifer-Ohlsonn et al., 1984) . One possible explanation for the discrepancy between our results and the various in vitro studies could lie in the intracellular distribution of p62c-mYc. In cultured cells c-myc gene product is of short half life and localised to the nucleus (Rabbits et al., 1985) . In this study a nuclear distribution was seen in the actively dividing cells of bone marrow and in some Tissue tumours. However, in most normal cells which show immunoreactivity the localisation of p62c-PyC was cytoplasmic. The pattern of staining of enterocytes and hepatocytes suggests that in these cells the protein was probably concentrated in the Golgi apparatus. This suggests that localisation of the protein, in vivo, may differ in cells which are dividing as opposed to those which are arrested or terminally differentiated.
In view of the unexpected results of this study the possibility of antibody cross-reactivity must obviously be considered. This is a serious problem when using single monoclonal antibodies. (Nigg et al., 1982) . However, in this study antibodies to separate parts of the p62c-myc were used and taken with the detailed characterisation of these antibodies, cross-reactivity would seem to be a highly unlikely explanation. The second problem lies in the sensitivity of the methods used. Immunohistochemical methods are known to be very sensitive but nevertheless it cannot be definitively stated that very low levels of p62c-mYc may not be detected and that these could have biological significance. Tissues were fixed rapidly after removal from the patient which therefore makes it unlikely that c-myc protein would have been significantly catabolised before fixation. A further possibility is that the intracellular distribution of p62c-myc was altered by fixation, either by diffusion, or some other mechanism. However, it is difficult to envisage how the observed tissue-specific differences in distribution could be accounted for by this type of artefact. Furthermore, the intense granular localisation seen in some cells (Figures 5 and 6) would not be consistent with fixation associated diffusion.
In conclusion, our study provides little evidence to support the view that elevated expression of cmyc is a common or necessary feature of Ihuimian malignant lymphomas. Widespread distribution of this protein in normal tissues raises a number of interesting questions concerning its function. These concern the possible differing functions of nuclear and cytoplasmic p62c-myc since it may be that one is active and the other a storage form of the molecule. It would also be relevant to ask whether c-myc is involved solely in the control of cell division or whether it participates in other aspects of cellular metabolism. These questions clearly merit further investigation. Finally, it does not appear that the immunocytochemical demonstration of p62c-mYc is of value in the pathological diagnosis or subtyping of malignant lymphomas.
